ClinicalTrials.gg

Program

garadacimab

Also written as “CSL312”, “Garadacimab” and “Factor XIIa antagonist monoclonal antibody”.

Its studies are mostly in Angioedemas, Hereditary · Idiopathic Pulmonary Fibrosis, led by CSL.

Furthest: phase 4, since Feb 3, 20259 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
CSL90 open or runningphase 4since Feb 3, 2025Oct 17, 2018none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 17, 2018First study: phase 2 study in Angioedemas, HereditaryFirst studyNCT03712228 · 44 enrolled · United States, Australia, Canada and more
  2. Feb 21, 2020Phase 2 study in PICC-associated ThrombosisNCT04281524
  3. Oct 2, 2020Phase 1 study in Healthy VolunteersNCT04580654 · 38 enrolled · United States
  4. Dec 1, 2020Phase 3 study in Angioedemas, HereditaryNCT04656418 · 64 enrolled · United States, Canada, Germany and more
  5. Feb 1, 2021Phase 3 study in Angioedemas, HereditaryNCT04739059 · 171 enrolled · United States, Australia, Canada and more
  6. Nov 12, 2021Phase 2 study in Idiopathic Pulmonary FibrosisNCT05130970 · 81 enrolled · United States, Australia, Austria and more
  7. Mar 23, 2022Phase 1 study in Healthy ParticipantsNCT05306275 · 132 enrolled · United States
  8. Apr 4, 2023Phase 3 study in Angioedemas, HereditaryNCT05819775 · 22 enrolled · United States, Australia, Canada and more
  9. Feb 3, 2025Phase 4 study in Angioedemas, HereditaryNCT06806657 · 18 enrolled · United States, Canada, Germany

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 9 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06806657Angioedemas, Hereditary · United States, Canada, Germany4CompletedJun 29, 202618
NCT05819775Angioedemas, Hereditary · United States, Australia, Canada and more3CompletedNov 19, 202522
NCT05306275Healthy Participants · United States1CompletedSep 27, 2022132
NCT05130970Idiopathic Pulmonary Fibrosis · United States, Australia, Austria and more2CompletedJan 2, 202481
NCT04739059Angioedemas, Hereditary · United States, Australia, Canada and more3CompletedNov 21, 2025171
NCT04656418Angioedemas, Hereditary · United States, Canada, Germany and more3CompletedJun 7, 202264
NCT04580654Healthy Volunteers · United States1CompletedMay 7, 202138
NCT04281524PICC-associated Thrombosis2WithdrawnAug 20210
NCT03712228Angioedemas, Hereditary · United States, Australia, Canada and more2CompletedOct 15, 202144

How it is read

Names in the registry

  • “CSL312”, 6 entries
  • “Garadacimab”, 2 entries
  • “Factor XIIa antagonist monoclonal antibody”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.